Money moves in silence. Download 2025 State of Venture Report: a data-driven analysis of active funds, unicorn, and family offices
About usSign in

Adjuvant Capital

WebsiteLinkedInTwittercbCrunchbase
Status
ACTIVE
Global HQ
New York, United States
Countries of investment
  • USA
Investment stages
  • Series B
Industries
  • Biotechnology
  • Health tech
  • AI
  • Fintech
About
Adjuvant Capital is a life sciences investment fund supporting companies developing vaccines, drugs, diagnostics, and devices for global health threats. They fund high-impact technologies tackling neglected diseases and underserved populations worldwide.
Min check size
$5M
Max check size
$50M
Fund size
NPS

Investment Thesis

Adjuvant Capital finances the most promising life science technologies for highburden public health challenges. They invest in innovative technologies to address highburden and neglected infectious diseases, maternal and child health, nutrition, and reproductive and sexual health.
Lead investor
Co Invest
Number of exits
Preferred contact method

Adjuvant Capital Contacts Information

Primary contact

Secondary contact

Portfolio

LimmaTech Biologics

Memo Therapeutics

Curevo Vaccine

Antiva Biosciences

Pulmocide

Excision BioTherapeutics

Frontier Nutrition

VitriVax

MinervaX

Evofem

Univercells

LakeShore Biopharma

ChromaCode

Fund number
Vintage Year
Net Internal Rate of Return
Investment Multiple
Capital Allocation
Management Fee
Carried Interest
AUM
Follow-on Investments
Graduation Rate
Write-Off Ratio
Last profile update timestamp